Long-term survival after surgical treatment followed by adjuvant systemic therapy for primary duodenal melanoma
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER JAPAN KK
Autores
SILVEIRA, Sergio do Prado
SANTOS, Elizabeth Santana dos
MEIRELLES, Luciana Rodrigues de
Citação
CLINICAL JOURNAL OF GASTROENTEROLOGY, v.13, n.4, p.532-537, 2020
Resumo
Primary mucosal malignant melanomas of the gastrointestinal tract are rare tumors associated to poor prognosis. Primary duodenal involvement by pigmented lesions is even more uncommon, and only a few reports exist in the literature. We report the case of a patient with large primary duodenal melanoma that presented with upper intestinal obstruction and bleeding that was submitted to urgent pancreaticoduodenectomy followed by adjuvant systemic therapy with an oral alkylating agent (temozolomide) plus intravenous cisplatin. The patient presents no signs of recurrence 3 years after the surgery. We consider that radical surgical resection followed by systemic therapy is a safe and effective treatment strategy option for primary mucosal gastrointestinal melanomas.
Palavras-chave
Melanoma, Duodenal neoplasms, Pancreaticoduodenectomy
Referências
- Akaraviputh T, 2010, WORLD J GASTROENTERO, V16, P745, DOI 10.3748/wjg.v16.i6.745
- AMAR A, 1992, GASTROEN CLIN BIOL, V16, P365
- Anvari K, 2018, CASP J INTERN MED, V9, P312, DOI 10.22088/cjim.9.3.312
- Avital S, 2004, AM SURGEON, V70, P649
- Bendic A, 2013, HEPATOB PANCREAT DIS, V12, P106, DOI 10.1016/S1499-3872(13)60016-8
- Blecker D, 1999, AM J GASTROENTEROL, V94, P3427, DOI 10.1111/j.1572-0241.1999.01604.x
- Bullard KM, 2003, J AM COLL SURGEONS, V196, P206, DOI 10.1016/S1072-7515(02)01538-7
- Buzaid AC, 1997, J CLIN ONCOL, V15, P1039, DOI 10.1200/JCO.1997.15.3.1039
- Capizzi Peter J., 1994, Comprehensive Therapy, V20, P20
- Cheng L, 2018, MODERN PATHOL, V31, P24, DOI 10.1038/modpathol.2017.104
- Cheung MC, 2008, J GASTROINTEST SURG, V12, P731, DOI 10.1007/s11605-007-0417-3
- Dupin E, 2003, ONCOGENE, V22, P3016, DOI 10.1038/sj.onc.1206460
- Flechon A, 2002, HISTOPATHOLOGY, V41, P562, DOI 10.1046/j.1365-2559.2002.01457_3.x
- Furlan A, 2018, DEV BIOL, V444, pS25, DOI 10.1016/j.ydbio.2018.02.008
- Grassetto G, 2011, PET CLIN, V6, P79, DOI 10.1016/j.cpet.2011.01.002
- Jain S, 2015, INDIAN J NUCL MED, V30, P89, DOI 10.4103/0972-3919.147560
- Karamanou M, 2012, J BUON, V17, P400
- Khalid U, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-14
- Khalil DN, 2014, HEMATOL ONCOL CLIN N, V28, P507, DOI 10.1016/j.hoc.2014.02.006
- Kilambi R, 2017, ANN ROY COLL SURG, V99, pE131, DOI 10.1308/rcsann.2016.0323
- Kim HS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-167
- KLAASE JM, 1990, BRIT J SURG, V77, P60, DOI 10.1002/bjs.1800770121
- Korkolis DP, 2008, SOUTH MED J, V101, P836, DOI 10.1097/SMJ.0b013e31817dfd75
- KRAUSZ MM, 1978, J SURG ONCOL, V10, P283, DOI 10.1002/jso.2930100402
- Lens M, 2009, LANCET ONCOL, V10, P516, DOI 10.1016/S1470-2045(09)70036-1
- LEPOOLE IC, 1993, J IMMUNOL, V151, P7284
- Li G, 2014, MOL CLIN ONCOL, V2, P233, DOI 10.3892/mco.2013.217
- Li HX, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-74
- Li Zhi-yu, 2008, Zhonghua Wai Ke Za Zhi, V46, P574
- Lian B, 2013, CLIN CANCER RES, V19, P4488, DOI 10.1158/1078-0432.CCR-13-0739
- Mackintosh JA, 2001, J THEOR BIOL, V211, P101, DOI 10.1006/jtbi.2001.2331
- Mihajlovic M, 2012, INT J CLIN EXP PATHO, V5, P739
- Rebecca VW, 2012, MELANOMA RES, V22, P114, DOI 10.1097/CMR.0b013e328351fa4d
- Sachs DL, 1999, J AM ACAD DERMATOL, V41, P1042, DOI 10.1016/S0190-9622(99)70273-2
- Suganuma T, 2013, CLIN J GASTROENTEROL, V6, P211, DOI 10.1007/s12328-013-0380-3
- Tacastacas JD, 2014, J AM ACAD DERMATOL, V71, P366, DOI 10.1016/j.jaad.2014.03.031
- WERDIN C, 1988, CANCER, V61, P1364, DOI 10.1002/1097-0142(19880401)61:7<1364::AID-CNCR2820610715>3.0.CO;2-B